Alpha 2.0
Login Register
» Authors » Peninah Soipei

Peninah Soipei

Explore the profile of Peninah Soipei including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 5
Citations 138
Followers 0
Related Specialties
Infectious Diseases
Tropical Medicine
General Medicine
Top 10 Co-Authors
Ermias Diro
Asrat Hailu
Koert Ritmeijer
Raymond Omollo
Jorge Alvar
Monique Wasunna
Fabiana Alves
Britta C Urban
Eduard E Zijlstra
Adrian V S Hill
Published In
PLoS Negl Trop Dis
PLoS One
Mol Ther
Clin Drug Investig
Affiliations
Soon will be listed here.
Recent Articles
1.
Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia
Diro E, Edwards T, Ritmeijer K, Fikre H, Abongomera C, Kibret A, et al.
PLoS Negl Trop Dis . 2019 Feb; 13(2):e0007132. PMID: 30789910
Background: The long-term treatment outcome of visceral leishmaniasis (VL) patients with HIV co-infection is complicated by a high rate of relapse, especially when the CD4 count is low. Although use...
2.
A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia
Diro E, Blesson S, Edwards T, Ritmeijer K, Fikre H, Admassu H, et al.
PLoS Negl Trop Dis . 2019 Jan; 13(1):e0006988. PMID: 30653490
Background: Visceral leishmaniasis (VL) in human immunodeficiency virus (HIV) co-infected patients requires special case management. AmBisome monotherapy at 40 mg/kg is recommended by the World Health Organization. The objective of...
3.
Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme
Kimutai R, Musa A, Njoroge S, Omollo R, Alves F, Hailu A, et al.
Clin Drug Investig . 2017 Jan; 37(3):259-272. PMID: 28066878
Introduction: In 2010, WHO recommended a new first-line treatment for visceral leishmaniasis (VL) in Eastern Africa. The new treatment, a combination of intravenous (IV) or intramuscular (IM) sodium stibogluconate (SSG)...
4.
Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations
Kimani D, Jagne Y, Cox M, Kimani E, Bliss C, Gitau E, et al.
Mol Ther . 2014 Jun; 22(11):1992-2003. PMID: 24930599
To induce a deployable level of efficacy, a successful malaria vaccine would likely benefit from both potent cellular and humoral immunity. These requirements are met by a heterologous prime-boost immunization...
5.
Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults
Ogwang C, Afolabi M, Kimani D, Jagne Y, Sheehy S, Bliss C, et al.
PLoS One . 2013 Mar; 8(3):e57726. PMID: 23526949
Background: Heterologous prime boost immunization with chimpanzee adenovirus 63 (ChAd63) and Modified vaccinia Virus Ankara (MVA) vectored vaccines is a strategy recently shown to be capable of inducing strong cell...